Avanos Medical, Inc. reported a total revenue of $701.2 million for the fiscal year ending December 31, 2025, reflecting a 1.9% increase from $687.8 million in 2024. The company's net loss for the year was $72.9 million, a significant improvement compared to a net loss of $392.1 million in the previous year. This improvement was primarily attributed to a reduction in goodwill impairment charges, which amounted to $77.0 million in 2025, compared to $436.7 million in 2024. The company's gross profit for 2025 was $353.9 million, down from $381.3 million in 2024, largely due to increased costs of products sold, which rose to $347.3 million from $306.5 million.
Avanos has undergone significant strategic changes, including the completion of two acquisitions: Nexus Medical, LLC for $27.0 million in September 2025, and Diros Technology Inc. for approximately $53.0 million in July 2023. The Nexus acquisition is expected to enhance Avanos's Specialty Nutrition Systems portfolio, while the Diros acquisition strengthens its Pain Management and Recovery segment. Additionally, the company divested its Respiratory Health business for $110.0 million in cash in October 2023, which is part of its ongoing transformation initiative aimed at focusing on higher-margin product lines.
Operationally, Avanos reported a total employee count of 2,287 as of December 31, 2025, with a significant portion of its workforce based in Mexico. The company has also seen a shift in its sales distribution, with approximately 49% of net sales in North America made through distributors. The Specialty Nutrition Systems segment generated $432.9 million in sales, a 9.2% increase from the previous year, driven by strong demand for enteral feeding products and neonate solutions. Conversely, the Pain Management and Recovery segment saw a modest increase of 1.5% in sales to $237.8 million, with radiofrequency ablation solutions experiencing a 10.1% growth.
Looking ahead, Avanos anticipates continued growth in its Specialty Nutrition Systems and Pain Management segments, supported by its recent acquisitions and ongoing product development efforts. The company is focused on executing its three-year restructuring initiative, which aims to streamline operations and enhance profitability. However, it also faces challenges such as inflationary pressures, supply chain disruptions, and regulatory compliance costs, which could impact its financial performance in the near term. The company remains committed to improving its operational efficiency and expanding its market presence while navigating these challenges.
About AVANOS MEDICAL, INC.
Avanos Medical, Inc. develops, manufactures, and markets medical devices focused on Digestive Health and Pain Management and Recovery. Its key products include enteral feeding tubes, neonatal feeding solutions, and non-opioid pain relief therapies such as surgical pain pumps and radiofrequency ablation devices. Serving hospitals and healthcare providers globally, Avanos emphasizes clinically effective, reliable solutions that improve patient outcomes and reduce healthcare costs through a broad distribution network and strong customer engagement.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.